CAS: 7333-51-9; Cyclohexyltriphenylphosphonium Bromide

上下游产品

CAS号108-85-0 溴代环己烷 | CAS号603-35-0 三苯基膦 | CAS号111-24-0 1,5-二溴戊烷 | CAS号19493-09-5 methylidene tri... | CAS号16666-81-2 cyclohexylidene... | CAS号696-32-2 difluoromethyli... | CAS号603-35-0 三苯基膦 | CAS号1608-31-7 Cyclohexylidene...

📜溴代环己烷,三苯基膦 以 甲苯 作为反应溶剂,化学反应 48.0H,以80%的收率获得产物环己基三苯基溴化膦
参考文献:均相和多相 Pd 催化选择性 C-P 活化和转移氢化用于"基团取代"合成三价膦
标题:均相和多相 Pd 催化选择性 C-P 活化和转移氢化用于"基团取代"合成三价膦
摘要:报道了通过鏻盐的 C-P 活化合成三价膦的"基团取代".通过膦的烷基化引入烷基以形成鏻盐.鏻盐的"去芳基化"是通过 C-P 活化和使用均相或非均相 Pd (0) 催化剂的转移氢化来实现的.采用这种方法,从市售的三芳基膦中制备了一系列三价膦.手性单膦配体可以从 Binap 在"脱膦"过程中制备.
DOI:10.1021/acs.Orglett.2C00844

专利信息

专利号:US-6825185-B2
优先权日:2000-12-21
标题:Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use
发明人：KHANAPURE SUBHASH P; GARVEY DAVID S; EARL RICHARD A; EZAWA MAIKO; FANG XINQIN; GASTON RICKY D
权利人:NITROMED INC
摘要:The invention describes novel substituted aryl compounds that are cyclooxygenase 2 (COX-2) selective inhibitors and novel compositions comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or, optionally, at least one therapeutic agent, such as, steroids, nonsterodal antiinflammatory compounds (NSAID), 5-lipoxygenase (5-LO) inhibitors, leukotriene B 4 (LTB 4 ) receptor antagonists, leukotriene A 4 (LTA 4 ) hydrolase inhibitors, 5-HT agonists, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitors, H 2 antagonists, antineoplastic agents, antiplatelet agents, thrombin inhibitors, thromboxane inhibitors, decongestants, diuretics, sedating or non-sedating anti-histamines, inducible nitric oxide synthase inhibitors, opioids, analgesics, Helicobacter pylori inhibitors, proton pump inhibitors, isoprostane inhibitors, and mixtures thereof. The invention also provides novel kits comprising at least one COX-2 selective inhibitor, and, optionally, at least one nitric oxide donor, and/or, optionally, at least one therapeutic agent. The novel cyclooxygenase 2 selective inhibitors of the invention can be optionally nitrosated and/or nitrosylated. The invention also provides methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 selective inhibitors; for facilitating wound healing; for treating and/or preventing renal toxicity or other toxicities; for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2; and for improving the cardiovascular profile of COX-2 selective inhibitors.